Sunday - January 25, 2026

Category Archives: Pharmaceuticals & Biotech

Chronic Urticaria Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Chronic Urticaria Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Chronic Urticaria pipeline landscape. It covers the Chronic Urticaria pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Chlorinated Paraffins (CPs): Applications in Plastics, Rubber, Lubricants & Environmental Guide

Chlorinated paraffins (CPs) are chlorinated derivatives of paraffin hydrocarbons. Their properties vary with chlorine content, and they are characterized by low volatility, flame retardancy, electrical insulation, and low cost. They play essential roles in industry as plasticizers, flame retardants, lubricants, … Continue reading →

Sickle Cell Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharma, Beam Therapeutics, Graphite Bio, Roche

The Key Sickle Cell Disease Companies in the market include – BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharmaceuticals, Beam Therapeutics Inc., Graphite Bio, Roche, Quercis Pharma, Editas Medicin, Pfizer, Emmaus Medical, Inc, Vertex Pharmaceuticals, CRISPR therapeutics, Bluebird Bio, Pfizer, Novo … Continue reading →

Rheumatoid Arthritis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Eli Lilly and Company, Philogen, I-Mab Biopharma, Teijin Pharma, Revolo

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Rheumatoid Arthritis pipeline constitutes 75+ key companies continuously working towards developing 80+ Rheumatoid Arthritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading →

The Market share for Tolebrutinib by Sanofi’s Set to Experience Tremendous Growth by 2034

Explore Sanofi’s tolebrutinib market outlook with a detailed sales forecast and market size analysis through 2034.   [Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on Tolebrutinib (Sanofi’s) providing insights into … Continue reading →

Stargardt Disease Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Nanoscope Therapeutics, Belite Bio, Biophytis, reVision Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Stargardt Disease pipeline constitutes 20+ key companies continuously working towards developing 20+ Stargardt Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading →

Dato-DXd by AstraZeneca and Daiichi Sankyo expected to drive market size of Antibody Drug Conjugates by 2034

Discover an in-depth Dato-DXd market report by a leading healthcare research firm, covering market landscape, growth trends, and forecast insights through 2034. [Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on … Continue reading →

22q11.2 Deletion Syndrome Market Set for Growth Through 2034, with the US Leading Demand and 185+ Associated Conditions Shaping Unmet Clinical Needs | DelveInsight

22q11.2 Deletion Syndrome Market 22q11.2 Deletion Syndrome Companies are Zynerba Pharmaceuticals, Inc., Nobias Therapeutics, Inc., Bausch Health Americas, Inc., and others. The United States represents the largest 22q11.2 deletion syndrome market compared with EU4, the United Kingdom, and Japan. The … Continue reading →